MIB-1 labelling index is an independent prognostic marker in primary breast cancer

被引:83
作者
Jansen, RLH
Hupperets, PSGJ
Arends, JW
Joosten-Achjanie, SR
Volovics, A
Schouten, HC
Hillen, HFP
机构
[1] Univ Hosp Maastricht, Div Hematol Oncol, Dept Internal Med, NL-6202 AZ Maastricht, Netherlands
[2] Univ Hosp Maastricht, Dept Pathol, NL-6202 AZ Maastricht, Netherlands
[3] Univ Maastricht, Dept Methodol & Stat, Maastricht, Netherlands
关键词
MIB-1; S-phase fraction; prognosis; breast cancer;
D O I
10.1038/bjc.1998.515
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The proliferative activity of a tumour is considered to be an important prognostic factor in primary breast cancer. We have investigated the prognostic value of the MIB-1 labelling index in 341 patients with primary breast cancer and compared the results with the S-phase fraction in 220 patients of the same cohort. All patients were treated in one hospital and had a median follow-up of 128 months. No correlation between MIB-1 labelling and S-phase fraction could be demonstrated. MIB-1 had prognostic value for disease-free survival in the whole group of patients (P < 0.001) and in the node-negative subgroup (P < 0.001). In multivariate analysis. MIB-1 was an independent prognostic factor (P = 0.004) besides axillary lymph node status (P = 0.001). In univariate analysis high S-phase fraction was associated with decreased overall survival (P = 0.04); however, not in multivariate analysis. Moreover, S-phase fraction had a borderline prognostic significance for post-relapse survival in multivariate analysis (P = 0.08). Thus, in conclusion, the growth fraction of a tumour as determined by the MIB-1 labelling index is an important prognostic factor in patients with primary breast cancer.
引用
收藏
页码:460 / 465
页数:6
相关论文
共 39 条
[1]   KI67 IMMUNOSTAINING IN PRIMARY BREAST-CANCER - PATHOLOGICAL AND CLINICAL ASSOCIATIONS [J].
BOUZUBAR, N ;
WALKER, KJ ;
GRIFFITHS, K ;
ELLIS, IO ;
ELSTON, CW ;
ROBERTSON, JFR ;
BLAMEY, RW ;
NICHOLSON, RI .
BRITISH JOURNAL OF CANCER, 1989, 59 (06) :943-947
[2]  
Brown RW, 1996, CLIN CANCER RES, V2, P585
[3]  
CLAYTON F, 1991, CANCER, V68, P1309, DOI 10.1002/1097-0142(19910915)68:6<1309::AID-CNCR2820680621>3.0.CO
[4]  
2-I
[5]   Prognostic impact of proliferation associated factors MIBI (Ki-67) and S-phase in node-negative breast cancer [J].
Dettmar, P ;
Harbeck, N ;
Thomssen, C ;
Pache, L ;
Ziffer, P ;
Fizi, K ;
Janicke, F ;
Nathrath, W ;
Schmitt, M ;
Graeff, H ;
Hofler, H .
BRITISH JOURNAL OF CANCER, 1997, 75 (10) :1525-1533
[6]  
Domagala W, 1996, CLIN CANCER RES, V2, P147
[7]   Comparison of MIB-1 proliferation index with S-phase fraction in human breast carcinomas [J].
Ellis, PA ;
Makris, A ;
Burton, SA ;
Titley, J ;
Ormerod, MG ;
Salter, J ;
Powles, TJ ;
Smith, IE ;
Dowsett, M .
BRITISH JOURNAL OF CANCER, 1996, 73 (05) :640-643
[8]   ROUTINE OR DELAYED AXILLARY DISSECTION FOR PRIMARY BREAST-CANCER [J].
EPSTEIN, RJ .
EUROPEAN JOURNAL OF CANCER, 1995, 31A (10) :1570-1573
[9]   Is routine axillary nodal dissection necessary in the treatment of breast cancer? Pro [J].
Fentiman, IS .
EUROPEAN JOURNAL OF CANCER, 1996, 32A (09) :1460-1461
[10]   CELL-PROLIFERATION OF BREAST-CANCER EVALUATED BY ANTI-BRDU AND ANTI-KI-67 ANTIBODIES - ITS PROGNOSTIC VALUE ON SHORT-TERM RECURRENCES [J].
GAGLIA, P ;
BERNARDI, A ;
VENESIO, T ;
CALDAROLA, B ;
LAURO, D ;
CAPPA, APM ;
CALDERINI, P ;
LISCIA, DS .
EUROPEAN JOURNAL OF CANCER, 1993, 29A (11) :1509-1513